WST insider transaction filings
WEST PHARMACEUTICAL SERVICES INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-15. Screen WST transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 2 filings by 1 insider — 15,659 shares, $5,443,749 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 2,818 shares @ $340.81 ($960,403) by Favorite Annette F, filed 2026-09-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Favorite Annette F — Sr. VP & Chief HR Officer | 2 | — | 6 legs · 15,659 sh · $5,443,749 | 12 |
| Lagarde Michel — President and CEO, Director | 1 | — | — | 6 |
| McMahon Robert W. — SVP & Chief Financial Officer | 1 | — | — | 6 |
| HAUGEN JANET BRUTSCHEA — Director | 1 | — | — | 1 |
Recent Form 4 filings — WEST PHARMACEUTICAL SERVICES INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Favorite Annette F — Sr. VP & Chief HR Officer | Option exercise (M): 2,500 @ $89.64 · Sale (S): 2,500 @ $345 · Option exercise (M): 2,500 @ $89.64 · Sale (S): 2,500 @ $355 · Option exercise (M): 2,524 @ $89.64 · Sale (S): 2,524 @ $365 · +3 more | EDGAR |
| 2026-09-10 | 4 | Favorite Annette F — Sr. VP & Chief HR Officer | Option exercise (M): 2,817 @ $83.47 · Sale (S): 2,817 @ $340.81 · Option exercise (M): 2,818 @ $83.47 · Sale (S): 2,818 @ $340.81 · Option exercise (M): 2,500 @ $89.64 · Sale (S): 2,500 @ $340.81 · +3 more | EDGAR |
| 2026-09-10 | 4 | Lagarde Michel — President and CEO, Director | Grant/award (A): 13,879 (derivative) @ $0 · Grant/award (A): 11,081 (derivative) @ $0 · Grant/award (A): 12,088 (derivative) @ $0 · Grant/award (A): 6,200 (derivative) @ $0 · Grant/award (A): 4,950 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | McMahon Robert W. — SVP & Chief Financial Officer | Option exercise (M): 794.47 · Tax withholding (F): 345.51 @ $351.37 · Option exercise (M): 6,354.74 · Tax withholding (F): 2,763.68 @ $351.37 · Option exercise (M): 6,354.74 (derivative) @ $0 · Option exercise (M): 794.47 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 46 (derivative) @ $359 | EDGAR |
| 2026-05-14 | 4 | Campbell Shane Alden — SVP, Proprietary Segment | Option exercise (M): 296.00 · Tax withholding (F): 84.33 @ $312.07 · Option exercise (M): 473.59 · Tax withholding (F): 134.93 @ $312.07 · Option exercise (M): 296.00 (derivative) @ $0 · Option exercise (M): 473.59 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Pucci Paolo — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | Michels Douglas A — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | Lockhart Stephen H — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | LAI GOLDMAN MYLA — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | Keller Deborah L — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | Joseph Molly — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | FRIEL ROBERT F — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | Feehery William F — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-05-06 | 4 | BUTHMAN MARK A — Director | Grant/award (A): 791 @ $0 | EDGAR |
| 2026-04-29 | 4 | Favorite Annette F — Sr. VP & Chief HR Officer | Option exercise (M): 2,817 @ $83.47 · Sale (S): 2,817 @ $305.20 · Option exercise (M): 2,817 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | Winters Chad — VP, Chief Accounting Officer | Option exercise (M): 896 @ $173.22 · Sale (S): 896 @ $300.67 · Option exercise (M): 896 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 52 (derivative) @ $250.64 | EDGAR |
| 2026-03-03 | 4 | Finch Norman D. Jr. — SVP, GC & Corporate Secretary | Grant/award (A): 1,285 (derivative) @ $0 · Grant/award (A): 3,057 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Green Eric Mark — President, CEO and Board Chair, Director | Grant/award (A): 6,986 (derivative) @ $0 · Grant/award (A): 16,630 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Favorite Annette F — Sr. VP & Chief HR Officer | Grant/award (A): 720 (derivative) @ $0 · Grant/award (A): 1,712 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Campbell Shane Alden — SVP, Proprietary Segment | Grant/award (A): 1,131 (derivative) @ $0 · Grant/award (A): 2,691 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | McMahon Robert W. — SVP & Chief Financial Officer | Grant/award (A): 3,082 (derivative) @ $0 · Grant/award (A): 7,337 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Poussot Rodolphe Jean — SVP, Strategy & Corporate Dev | Grant/award (A): 437 (derivative) @ $0 · Grant/award (A): 1,040 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Winters Chad — VP, Chief Accounting Officer | Grant/award (A): 340 (derivative) @ $0 · Grant/award (A): 808 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Poussot Rodolphe Jean — SVP, Strategy & Corporate Dev | Option exercise (M): 383.38 · Tax withholding (F): 129.54 @ $241.12 · Option exercise (M): 383.38 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Witherspoon Charles — VP & Treasurer | Option exercise (M): 60.22 · Tax withholding (F): 22.07 @ $241.12 · Option exercise (M): 60.22 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Winters Chad — VP, Chief Accounting Officer | Option exercise (M): 89.33 · Tax withholding (F): 30.18 @ $241.12 · Option exercise (M): 89.33 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Poussot Rodolphe Jean — SVP, Strategy & Corporate Dev | Option exercise (M): 82.30 · Tax withholding (F): 27.81 @ $248.26 · Option exercise (M): 82.30 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Witherspoon Charles — VP & Treasurer | Grant/award (A): 115.91 @ $0 · Tax withholding (F): 41.52 @ $243.19 | EDGAR |
| 2026-02-19 | 4 | Winters Chad — VP, Chief Accounting Officer | Grant/award (A): 149.68 @ $0 · Tax withholding (F): 50.58 @ $243.19 | EDGAR |
| 2026-02-19 | 4 | Green Eric Mark — President, CEO and Board Chair, Director | Grant/award (A): 4,418.77 @ $0 · Tax withholding (F): 1,305.38 @ $243.19 · Option exercise (M): 1,318.81 · Tax withholding (F): 573.55 @ $248.26 · Option exercise (M): 1,318.81 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Favorite Annette F — Sr. VP & Chief HR Officer | Grant/award (A): 441.96 @ $0 · Tax withholding (F): 150.44 @ $243.19 · Option exercise (M): 135.49 · Tax withholding (F): 35.76 @ $248.26 · Option exercise (M): 135.49 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | McMahon Robert W. — SVP & Chief Financial Officer | Option exercise (M): 4,230.52 · Tax withholding (F): 1,250.03 @ $246.16 · Option exercise (M): 4,230.52 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 46 (derivative) @ $275.14 | EDGAR |
| 2025-12-10 | 4 | Finch Norman D. Jr. — SVP, GC & Corporate Secretary | Grant/award (A): 192 (derivative) @ $0 · Grant/award (A): 459 (derivative) @ $269.08 | EDGAR |
| 2025-10-02 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 48 (derivative) @ $262.33 | EDGAR |
| 2025-08-12 | 4 | McMahon Robert W. — SVP & Chief Financial Officer | Grant/award (A): 12,670 (derivative) @ $0 · Grant/award (A): 3,168 (derivative) @ $0 · Grant/award (A): 7,647 (derivative) @ $240.33 · Grant/award (A): 7,137 (derivative) @ $240.33 | EDGAR |
| 2025-07-01 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 58 (derivative) @ $218.80 | EDGAR |
| 2025-05-14 | 4 | Campbell Shane Alden — SVP, Proprietary Segment | Grant/award (A): 1,891 (derivative) @ $0 · Grant/award (A): 1,182 (derivative) @ $0 · Grant/award (A): 2,852 (derivative) @ $219.46 | EDGAR |
| 2025-05-08 | 4 | HAUGEN JANET BRUTSCHEA — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | FRIEL ROBERT F — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | LAI GOLDMAN MYLA — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | Joseph Molly — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | Hofmann Thomas W — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | Keller Deborah L — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | Feehery William F — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | Lockhart Stephen H — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
| 2025-05-08 | 4 | BUTHMAN MARK A — Director | Grant/award (A): 1,071 @ $0 | EDGAR |
Recent 8-K events — WEST PHARMACEUTICAL SERVICES INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K/A | ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=WST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →